Drybench Patent.
GLECAPREVIR; PIBRENTASVIR, NDA 209394
The patents and exclusivities FDA's Orange Book lists for NDA 209394 as captured on 14 October 2026, each date named by its rule and its rows, and any rows of FDA's Paragraph IV list captured on 17 October 2026 that give this NDA's number. Listed protection is a range of dates, never one date.
FDA capture · review pending. Each row is shown as captured from FDA's Orange Book files and Paragraph IV list. Dates are FDA's own; spreadsheet day numbers are shown as dates, and a cell that cannot be read as one date is shown as written and left out of the range. Where FDA lists a *PED row without flags, its flags are read from the base row and marked so. A Paragraph IV row is placed here only by the number in its RLD/NDA cell; nothing is joined by name. How this page reads FDA's files has not been independently reviewed by a regulatory-affairs reviewer.
- Orange Book captured
- 14 October 2026
- Paragraph IV list captured
- 17 October 2026
- Last checked
- 30 October 2026
- Data-branch commit
- dadcab56563716abea6c5e31a5e1970080c778ef
Listed protection is a range of the dates FDA lists, not a forecast of market entry, and not legal, regulatory or investment advice.
Dates as listed in FDA's Orange Book capture of 14 October 2026. This page does not say whether a date has passed; compare it with today's date and FDA's current Orange Book. This page shows only what the capture of 14 October 2026 lists. It does not show patents or exclusivities listed before and since removed.
Listed protection
Listed dates run from 30 Apr 2026 to 24 Dec 2036, each by its own rule; no one date stands for this product.
- Earliest listed date
- 30 Apr 2026ODE-232 exclusivityRule R3 · Product 001
Source lines
exclusivity.txt line 776
- Latest listed date
- 24 Dec 2036US 11,246,866 with pediatric exclusivity, as listedRule R2 · Product 001
Source lines
patent.txt line 10,305
- Latest substance patent
- 5 Dec 2035US 9,321,807 with pediatric exclusivity, as listedRule R2 · Product 001
Source lines
patent.txt line 10,316
- Latest listed patent
- 24 Dec 2036US 11,246,866 with pediatric exclusivity, as listedRule R2 · Product 001
Source lines
patent.txt line 10,305
- Latest exclusivity
- 10 Dec 2028PED exclusivityRule R3 · Product 001
Source lines
exclusivity.txt line 779
Listed dates of other NDAs in the same years:20262028203020312032203420352036
16 use-code patents, blocking the coded use only
Products
Each product number FDA lists under NDA 209394, as listed. The sections below name products by these numbers.
Product 001 · MAVYRET
- Dosage form; route
- TABLET;
ORAL - Strength
- 100MG;40MG
- Approval date as listed
- 3 Aug 2017
- Type as listed
- RX
- Applicant as listed
- ABBVIE INC
Listed patents
Every patent the FDA lists for this product, as the application holder submitted it, with its flags. The FDA does not verify listings.
30 entries from 30 rows as listed; rows merge only where every cell shown is the same, each with its product numbers.
US 10,028,937, use patent
patent.txt line 10,295- Expiry as listed
- 10 Jun 2030
- Rule
- R1
- Flags
- use code U-2141
- Product numbers
- 001
US 10,028,937, use patent
patent.txt line 10,296- Expiry as listed
- 10 Jun 2030
- Rule
- R1
- Flags
- use code U-3237
- Product numbers
- 001
US 10,028,937, use patent
patent.txt line 10,297- Expiry as listed
- 10 Jun 2030
- Rule
- R1
- Flags
- use code U-4206
- Product numbers
- 001
US 10,039,754, use patent
patent.txt line 10,299- Expiry as listed
- 10 Jun 2030
- Rule
- R1
- Flags
- use code U-2141
- Product numbers
- 001
US 10,039,754, use patent
patent.txt line 10,300- Expiry as listed
- 10 Jun 2030
- Rule
- R1
- Flags
- use code U-3237
- Product numbers
- 001
US 10,039,754, use patent
patent.txt line 10,301- Expiry as listed
- 10 Jun 2030
- Rule
- R1
- Flags
- use code U-4206
- Product numbers
- 001
US 9,586,978, use patent
patent.txt line 10,319- Expiry as listed
- 6 Nov 2030
- Rule
- R1
- Flags
- use code U-2141
- Product numbers
- 001
US 9,586,978, use patent
patent.txt line 10,320- Expiry as listed
- 6 Nov 2030
- Rule
- R1
- Flags
- use code U-3237
- Product numbers
- 001
US 9,586,978, use patent
patent.txt line 10,321- Expiry as listed
- 6 Nov 2030
- Rule
- R1
- Flags
- use code U-4206
- Product numbers
- 001
US 10,028,937 with pediatric exclusivity, as listed
patent.txt line 10,294- Expiry as listed
- 10 Dec 2030
- Rule
- R2
- Flags
- pediatric, as listed by FDA (from the base row)
- Product numbers
- 001
US 10,039,754 with pediatric exclusivity, as listed
patent.txt line 10,298- Expiry as listed
- 10 Dec 2030
- Rule
- R2
- Flags
- pediatric, as listed by FDA (from the base row)
- Product numbers
- 001
US 9,586,978 with pediatric exclusivity, as listed
patent.txt line 10,318- Expiry as listed
- 6 May 2031
- Rule
- R2
- Flags
- pediatric, as listed by FDA (from the base row)
- Product numbers
- 001
US 8,648,037, substance and product and use patent
patent.txt line 10,311- Expiry as listed
- 19 Jan 2032
- Rule
- R1
- Flags
- substance · product · use code U-2141
- Product numbers
- 001
US 8,648,037, substance and product and use patent
patent.txt line 10,312- Expiry as listed
- 19 Jan 2032
- Rule
- R1
- Flags
- substance · product · use code U-3237
- Product numbers
- 001
US 8,648,037, substance and product and use patent
patent.txt line 10,313- Expiry as listed
- 19 Jan 2032
- Rule
- R1
- Flags
- substance · product · use code U-4206
- Product numbers
- 001
US 8,937,150, substance and product patent
patent.txt line 10,315- Expiry as listed
- 18 May 2032
- Rule
- R1
- Flags
- substance · product
- Product numbers
- 001
US 8,648,037 with pediatric exclusivity, as listed
patent.txt line 10,310- Expiry as listed
- 19 Jul 2032
- Rule
- R2
- Flags
- substance · product · pediatric, as listed by FDA (from the base row)
- Product numbers
- 001
US 8,937,150 with pediatric exclusivity, as listed
patent.txt line 10,314- Expiry as listed
- 18 Nov 2032
- Rule
- R2
- Flags
- substance · product · pediatric, as listed by FDA (from the base row)
- Product numbers
- 001
US 10,286,029, use patent
patent.txt line 10,303- Expiry as listed
- 14 Mar 2034
- Rule
- R1
- Flags
- use code U-3237
- Product numbers
- 001
US 10,286,029, use patent
patent.txt line 10,304- Expiry as listed
- 14 Mar 2034
- Rule
- R1
- Flags
- use code U-4206
- Product numbers
- 001
US 11,484,534, use patent
patent.txt line 10,308- Expiry as listed
- 14 Mar 2034
- Rule
- R1
- Flags
- use code U-3237
- Product numbers
- 001
US 11,484,534, use patent
patent.txt line 10,309- Expiry as listed
- 14 Mar 2034
- Rule
- R1
- Flags
- use code U-4206
- Product numbers
- 001
US 10,286,029 with pediatric exclusivity, as listed
patent.txt line 10,302- Expiry as listed
- 14 Sep 2034
- Rule
- R2
- Flags
- pediatric, as listed by FDA (from the base row)
- Product numbers
- 001
US 11,484,534 with pediatric exclusivity, as listed
patent.txt line 10,307- Expiry as listed
- 14 Sep 2034
- Rule
- R2
- Flags
- pediatric, as listed by FDA (from the base row)
- Product numbers
- 001
US RE48923, substance patent
patent.txt line 10,323- Expiry as listed
- 8 May 2035
- Rule
- R1
- Flags
- substance
- Product numbers
- 001
US 9,321,807, substance patent
patent.txt line 10,317- Expiry as listed
- 5 Jun 2035
- Rule
- R1
- Flags
- substance
- Product numbers
- 001
US RE48923 with pediatric exclusivity, as listed
patent.txt line 10,322- Expiry as listed
- 8 Nov 2035
- Rule
- R2
- Flags
- substance · pediatric, as listed by FDA (from the base row)
- Product numbers
- 001
US 9,321,807 with pediatric exclusivity, as listed
patent.txt line 10,316- Expiry as listed
- 5 Dec 2035
- Rule
- R2
- Flags
- substance · pediatric, as listed by FDA (from the base row)
- Product numbers
- 001
US 11,246,866, product patent
patent.txt line 10,306- Expiry as listed
- 24 Jun 2036
- Rule
- R1
- Flags
- product
- Product numbers
- 001
US 11,246,866 with pediatric exclusivity, as listed
patent.txt line 10,305- Expiry as listed
- 24 Dec 2036
- Rule
- R2
- Flags
- product · pediatric, as listed by FDA (from the base row)
- Product numbers
- 001
Listed exclusivities
Each exclusivity FDA lists for NDA 209394, with its code, FDA's definition of the code where the store's code list gives one, and its date as listed.
ODE-232 exclusivity
exclusivity.txt line 776- Date
- 30 Apr 2026
- Rule
- R3
- Definition
- Orphan drug exclusivity (to be checked against FDA's list)
- Product numbers
- 001
ODE-233 exclusivity
exclusivity.txt line 777- Date
- 30 Apr 2026
- Rule
- R3
- Definition
- Orphan drug exclusivity (to be checked against FDA's list)
- Product numbers
- 001
PED exclusivity
exclusivity.txt lines 780–781- Date
- 30 Oct 2026
- Rule
- R3
- Definition
- Pediatric exclusivity (to be checked against FDA's list)
- Product numbers
- 001
I-967 exclusivity
exclusivity.txt line 775- Date
- 10 Jun 2028
- Rule
- R3
- Definition
- New indication (to be checked against FDA's list)
- Product numbers
- 001
ODE-372 exclusivity
exclusivity.txt line 778- Date
- 10 Jun 2028
- Rule
- R3
- Definition
- Orphan drug exclusivity (to be checked against FDA's list)
- Product numbers
- 001
PED exclusivity
exclusivity.txt line 779- Date
- 10 Dec 2028
- Rule
- R3
- Definition
- Pediatric exclusivity (to be checked against FDA's list)
- Product numbers
- 001
Paragraph IV list rows giving NDA 209394
The rows of FDA's Paragraph IV certifications list as captured on 17 October 2026 whose RLD/NDA cell gives NDA 209394, each cell as listed.
Rows with no NDA number this page can match are kept apart on the list page; some may concern this product.
No row of the Paragraph IV list captured on 17 October 2026 gives NDA 209394 in its RLD/NDA cell. This does not mean no certification was submitted or that no application challenges a patent listed here.
Notes from the trace
- R6 tentative approvals: not in the Orange Book data files as captured; the Drugs@FDA join is a later ruling.
Patents vs FDA exclusivityHow to read the Orange Book data filesParagraph IV certificationWhat changed, by week